@article{ba3422e2d8f746cfb6cc59283fc3a7e3,
title = "Clinical implementation of RNA sequencing for Mendelian disease diagnostics",
abstract = "Background: Lack of functional evidence hampers variant interpretation, leaving a large proportion of individuals with a suspected Mendelian disorder without genetic diagnosis after whole genome or whole exome sequencing (WES). Research studies advocate to further sequence transcriptomes to directly and systematically probe gene expression defects. However, collection of additional biopsies and establishment of lab workflows, analytical pipelines, and defined concepts in clinical interpretation of aberrant gene expression are still needed for adopting RNA sequencing (RNA-seq) in routine diagnostics. Methods: We implemented an automated RNA-seq protocol and a computational workflow with which we analyzed skin fibroblasts of 303 individuals with a suspected mitochondrial disease that previously underwent WES. We also assessed through simulations how aberrant expression and mono-allelic expression tests depend on RNA-seq coverage. Results: We detected on average 12,500 genes per sample including around 60% of all disease genes—a coverage substantially higher than with whole blood, supporting the use of skin biopsies. We prioritized genes demonstrating aberrant expression, aberrant splicing, or mono-allelic expression. The pipeline required less than 1 week from sample preparation to result reporting and provided a median of eight disease-associated genes per patient for inspection. A genetic diagnosis was established for 16% of the 205 WES-inconclusive cases. Detection of aberrant expression was a major contributor to diagnosis including instances of 50% reduction, which, together with mono-allelic expression, allowed for the diagnosis of dominant disorders caused by haploinsufficiency. Moreover, calling aberrant splicing and variants from RNA-seq data enabled detecting and validating splice-disrupting variants, of which the majority fell outside WES-covered regions. Conclusion: Together, these results show that streamlined experimental and computational processes can accelerate the implementation of RNA-seq in routine diagnostics.",
keywords = "Genetic diagnostics, Mendelian diseases, RNA-seq",
author = "Y{\'e}pez, {Vicente A.} and Mirjana Gusic and Robert Kopajtich and Christian Mertes and Smith, {Nicholas H.} and Alston, {Charlotte L.} and Rui Ban and Skadi Beblo and Riccardo Berutti and Holger Blessing and El{\.z}bieta Ciara and Felix Distelmaier and Peter Freisinger and Johannes H{\"a}berle and Hayflick, {Susan J.} and Maja Hempel and Itkis, {Yulia S.} and Yoshihito Kishita and Thomas Klopstock and Krylova, {Tatiana D.} and Costanza Lamperti and Dominic Lenz and Christine Makowski and Signe Mosegaard and M{\"u}ller, {Michaela F.} and Gerard Mu{\~n}oz-Pujol and Agnieszka Nadel and Akira Ohtake and Yasushi Okazaki and Elena Procopio and Thomas Schwarzmayr and Jo{\'e}l Smet and Christian Staufner and Stenton, {Sarah L.} and Strom, {Tim M.} and Caterina Terrile and Frederic Tort and {Van Coster}, Rudy and Arnaud Vanlander and Matias Wagner and Manting Xu and Fang Fang and Daniele Ghezzi and Mayr, {Johannes A.} and Dorota Piekutowska-Abramczuk and Antonia Ribes and Agn{\`e}s R{\"o}tig and Taylor, {Robert W.} and Wortmann, {Saskia B.} and Kei Murayama and Thomas Meitinger and Julien Gagneur and Holger Prokisch",
note = "Funding Information: We are grateful to the patients, their families, and the referring clinicians for their participation in the study. We thank the Sequencing Core Facility of the HelmholtzZentrum M{\"u}nchen for providing sequencing service. Figure 1 was created with BioRender.com. Funding Information: Open Access funding enabled and organized by Projekt DEAL. The Bavarian State Ministry of Health and Care funded this work within its framework of DigiMed Bayern (grant number DMB-1805-0002). The German Bundesministerium f{\"u}r Bildung und Forschung (BMBF) supported the study through the ERA PerMed project PerMiM (01KU2016A to VAY, HP, and JG), the Medical Informatics Initiative CORD-MI (Collaboration on Rare Diseases) to VAY, the project MechML (01IS18053F to MM), the German Network for Mitochondrial Disorders (mitoNET; 01GM1113C to HP), and the E-Rare project GENOMIT (01GM1207 to HP). MG was supported by the DZHG (German Centre for Cardiovascular Research). JG is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - NFDI 1/1 “GHGA - German Human Genome-Phenome Archive”. The Bavaria California Technology Center supported CM through a fellowship. RWT is supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation, and the UK NHS Specialised Commissioners who fund the “Rare Mitochondrial Disorders of Adults and Children” Service in Newcastle upon Tyne. CLA is supported by a National Institute for Health Research (NIHR) Post-Doctoral Fellowship (PDF-2018-11-ST2-021). This work was supported by the Practical Research Project for Rare/Intractable Diseases (JP20ek0109468, JP19ek0109273) from the Agency for Medical Research and Development (AMED) and the Grants in Aid for Scientific Research (KAKENHI JP20H05519) from the Japan Society for the Promotion of Science (JSPS). This research was supported by the Instituto de Salud Carlos III (PI16/01048; PI19/01310) (Co-funded by European Regional Development Fund “A way to make Europe”) and the Centro de Investigaci{\'o}n Biom{\'e}dica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovaci{\'o}n, Spain). The present study was supported by the Departament de Salut, Generalitat de Catalunya (URDCAT project, SLT002/16/00174). This study was supported by the Ag{\`e}ncia de Gesti{\'o} d'Ajuts Universitaris i de Recerca (AGAUR) (2017: SGR 1428) and the CERCA Programme/Generalitat de Catalunya. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1186/s13073-022-01019-9",
language = "English (US)",
volume = "14",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "1",
}